The BioNTech SE ADR BNTX slid 2.69% to $112.51 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and the ...

The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the ...

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

As of 30 August at 09:30 GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

As of 16 September at 11:24 GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The ...

A cancer drug in-licensed by German biotech major BioNTech (Nasdaq: BNTX) from China-based Biotheus could be a good one, if mid-stage results shared at the European Society for Medical Oncology (ESMO) ...

Fintel reports that on September 16, 2024, JP Morgan upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...